AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

Trial Profile

AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 May 2018

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Autoimmune disorders; Pulmonary alveolar proteinosis
  • Focus Adverse reactions; Registrational
  • Acronyms IMPALA-EX
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 09 May 2018 According to the Savara Pharmaceuticals media release, first patient has been enrolled in this study.
    • 06 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top